The Nebraska Medical Association

https://www.nebmed.org/

 

Nebraska Oncology Society
07:33

Nebraska Oncology Society

Targeted Therapy for mNSCLC: What Is the Response Rate With Selpercatinib in RET+ Disease? How Do Treatment Options for MET Exon 14 Compare?

FEATURING Gregory Riely
  • 199 views
  • March 5, 2021
  • 2
15:24

Nebraska Oncology Society

NSCLC Targeted Therapies Update: Should We Consider EGFR Targeted Therapy in Adjuvant Setting?

FEATURING Gregory Riely
  • 159 views
  • March 5, 2021
  • 1
09:41

Nebraska Oncology Society

ASCO 2020 Review of Transoral Robotic Surgery for OPC : Is 2-yr PFS Favorable Without Post-Operative Therapy for Low-risk Disease Patients?

FEATURING Eric Sherman
  • 13 views
  • January 5, 2021
09:24

Nebraska Oncology Society

2020 ASCO LA-HNSCC Trials Review: What Is the Efficacy of Weekly CDDP vs. 3-Weekly CDDP?

FEATURING Eric Sherman
  • 13 views
  • January 5, 2021
11:38

Nebraska Oncology Society

ASCO 2020 Update on DO-IMRT & HNC Metastatic: Does Change in IMRT Lead to Improvement in Swallowing Function? What Are the KEYNOTE-048 Final Results Not Telling Us?

FEATURING Eric Sherman
  • 20 views
  • January 5, 2021
04:56

Nebraska Oncology Society

2020 ASCO Update on Metastatic/Recurrent HNSCC: What Is the Efficacy and Tolerance of Carboplatin-Cetuximab? Is Single-Agent Chemotherapy Sufficient?

FEATURING Eric Sherman
  • 15 views
  • January 5, 2021
08:09

Nebraska Oncology Society

2020 ASCO Update on RET-Altered Thyroid Cancer: What Is the Efficacy of New RET Inhibitors? Should We Use Them 1L or 2L?

FEATURING Eric Sherman
  • 25 views
  • January 5, 2021
06:13

Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on Advanced UC: Is Atezo Beneficial for DFS in High-Risk Muscle-Invasive Disease? Should We Add Avelumab After 1L Platinum-Based Chemo?

FEATURING Nicholas Vogelzang
  • 48 views
  • December 7, 2020
17:42

Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on PC: Does 18F-DCFPyL-PET/CT Propose a Change in Biochemically Relapsed Disease? Can Enzalutamide Delay Mets in Men With CRPC? Does Darolutamide Prolong OS?

FEATURING Nicholas Vogelzang
  • 118 views
  • December 7, 2020
13:26

Nebraska Oncology Society

Nebraska Oncology Society 2020 Update on Advanced RCC: Is 1L Pembro+Axitinib More Beneficial for OS/PFS vs. Sunitiniby? What Is the ORR With Nivo+Ipi vs. Nivo Mono in Treatment-Naïve Patients?

FEATURING Nicholas Vogelzang
  • 170 views
  • December 7, 2020
11:59

Nebraska Oncology Society

2020 ASCO mCRC Updates Recap: Did We Experience Pseudoprogression With Pembro? Is Toxicity Equally Important as Efficacy? Should We Still Use SCRT as a SoC?

FEATURING George Kim
  • 48 views
  • November 30, 2020
05:11

Nebraska Oncology Society

2020 ASCO Updates on GI Cancers: Is Chemo w/ mFOLFIRINOX More Effective vs. Gemcitabine/nab-Paclitaxel in Resectable PDAC? Should We Use 1L Donafenib vs. Sorafenib in Advanced HCC?

FEATURING George Kim
  • 13 views
  • November 30, 2020
10:06

Nebraska Oncology Society

2020 ASCO Highlights on Advanced CRC: Does mFOLFIRINOX Show DFS Benefit vs. Chemoradiation Among LARC Patients? Is Encorafenib+Cetuximab+/-Binimetinib Effective for BRAF V600E Mutations? What Is the ORR With T-DXd in HER2+ Metastatic Disease?

FEATURING George Kim
  • 15 views
  • November 30, 2020
04:13

Nebraska Oncology Society

2020 ASCO Updates on mCRC: Is Adjuvant mFOLFOX Superior to Hepatectomy Alone for Liver Metastases?

FEATURING George Kim
  • 25 views
  • November 30, 2020
07:52

Nebraska Oncology Society

2020 ASCO Highlights on Stage 3 Colon Cancer: What Are the DFS/OS Differences Between 3 vs. 6 Months of Adjuvant FOLFOX/CAPOX? Is the Addition of Celecoxib Beneficial?

FEATURING George Kim
  • 21 views
  • November 30, 2020
10:48

Nebraska Oncology Society

KEYNOTE-177 2020 ASCO Update on MSI-H/dMMR mCRC: Does Pembro Improve PFS vs. Chemo? Is It Practice Changing?

FEATURING George Kim
  • 28 views
  • November 30, 2020
07:39

Nebraska Oncology Society

ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III Trials? How Effective Is Lurbinectedin in Stage IV Disease Progressed After 1L Therapy?

FEATURING Gregory Riely
  • 93 views
  • October 13, 2020
16:08

Nebraska Oncology Society

Stage IV NSCLC 2020 Update: Is There a Benefit to Short-Course Chemotherapy and IO Combination in Disease Without an Oncogenic Driver?

FEATURING Gregory Riely
  • 122 views
  • October 13, 2020
30:39

Nebraska Oncology Society

2020 ASCO Updates on IO in Advanced Melanoma: What Are the Outcomes With Different Ipi+Nivo Combinations? How Do Targeted Therapy Agents Compare to IO? Does Pembro Lead to Lower irAEs?

FEATURING Shailender Bhatia
  • 65 views
  • October 12, 2020
10:23

Nebraska Oncology Society

2020 ASCO Highlights on Neoadjuvant IO in Stage 3 Melanoma: Does Ipi Lead to Lower Toxicity? Are There Benefits Over Standard Therapy?

FEATURING Shailender Bhatia
  • 43 views
  • October 12, 2020
21:02

Nebraska Oncology Society

2020 ASCO Updates on Frontline Multiple Myeloma: KRd vs. VRd - What Does the PFS/OS Analysis Suggest?

FEATURING Adam D. Cohen
  • 302 views
  • October 12, 2020
25:01

Nebraska Oncology Society

2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer Survival Benefit? What Are the Response Rates With Teclistamab?

FEATURING Adam D. Cohen
  • 335 views
  • October 12, 2020
  • 1